GlassScriptPhysician profile
Jasmin Woo
NPI 1841971025
$7,938.20
in general payments reported to CMS, 2019-2025
21 companies · $5,906 in 2025
The $5,906 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $271 · 2024: $1,761 · 2025: $5,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,713 · Consulting Fee: $2,130 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,713.21 |
| Consulting Fee | $2,130.00 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,482.31 | 2024-2025 | Zoryve |
| Regeneron Pharmaceuticals, INC. | $1,359.36 | 2025 | Dupixent |
| Janssen Biotech, INC. | $613.47 | 2024-2025 | Tremfya |
| Pfizer INC. | $608.34 | 2023-2025 | |
| Ucb, INC. | $601.25 | 2024-2025 | Bimzelx |
| Incyte Corporation | $566.18 | 2023-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $465.78 | 2024-2025 | Nemluvio |
| Abbvie INC. | $423.41 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $287.89 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $280.40 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $261.20 | 2023-2025 | |
| Genzyme Corporation | $226.36 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $189.54 | 2025 | |
| Leo Pharma INC. | $135.69 | 2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $130.93 | 2024 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $88.25 | 2023-2025 | Ilumya |
| Dermavant Sciences, INC. | $87.69 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.93 | 2024 | Cabtreo |
| Cipher Pharmaceuticals US LLC | $23.80 | 2025 | Natroba, Spinosad |
| Organon LLC | $20.30 | 2025 | Vtama |
| Botanix Sb INC | $19.12 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmin Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.